San Antonio, TX Clinical Trials Report — April 2026

For San Antonians considering participation in clinical research, April 2026 presents a critical window to join studies before enrollment concludes. Across San Antonio, 71 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 11 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

New Opportunities for San Antonio Volunteers

This month, San Antonio saw the opening of 15 new clinical trials, a decrease from the 21 trials that launched in March 2026. Despite this dip in new openings, the city continues to be a vibrant hub for medical research, with a total of 971 clinical trials currently recruiting across 545 research facilities.

Among the new trials, 3 are actively seeking healthy volunteers, adding to the 89 total trials currently recruiting healthy participants in San Antonio. This provides numerous avenues for those interested in supporting medical research without a specific medical condition.

Spotlight on Notable New Research

April brings several high-profile new trials to San Antonio, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy.
• Eli Lilly and Company is initiating NCT07545759, "A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)." This Phase 2 study, designed for 531 participants, will evaluate how well brenipatide is tolerated, its side effects, and its safety and efficacy.
• Kinaset Therapeutics Inc is sponsoring NCT07532265, "A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma." This Phase 2 dose-ranging study aims to evaluate the efficacy and safety of Frevecitinib over a 12-week treatment period in 512 participants with severe asthma not controlled by standard treatments.
• Housey Healthcare ULC is leading NCT07546929, "HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes." This Phase 2 study, involving 300 participants, will investigate the safety and efficacy of HP-211 for controlling blood sugar levels in patients with Type 2 Diabetes.
• Eccogene is sponsoring NCT07505303, "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial." This Phase 2 trial, aiming for 160 participants, will evaluate the effect of oral ECC4703 on body weight reduction and liver fat content.
• Eli Lilly and Company is also sponsoring NCT07533006, "A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)." This Phase 2 study, for 60 participants, will evaluate the effectiveness and safety of LY4005130 compared to placebo for severe hair loss.

New trials this month are exploring a range of conditions, including adult obesity, advanced breast cancer, advanced/metastatic colorectal adenocarcinoma, alopecia areata, breast cancer, castration-resistant prostate cancer (CRPC), cervical cancer, chronic inducible urticaria, chronic spontaneous urticaria, and diabetes. Drug trials account for the majority of new studies, with 13 new drug trials, followed by 2 device trials.

San Antonio's Leading Research Facilities

San Antonio is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Texas Health Science Center at San Antonio (94 trials)
• NEXT Oncology (51 trials)
• Research Site (39 trials)
• Children's Hospital of San Antonio (32 trials)
• Methodist Children's Hospital of South Texas (25 trials)
• The University of Texas Health Science Center at San Antonio (20 trials)
• START San Antonio (19 trials)
• Texas Oncology - San Antonio (15 trials)
• UT Health San Antonio (15 trials)
• Texas Dermatology and Laser Specialists (14 trials)
• Endeavor Clinical Trials (11 trials)
• Next Oncology (10 trials)

These institutions offer a broad spectrum of research, from oncology at NEXT Oncology and START San Antonio, to diverse medical fields at the University of Texas Health Science Center at San Antonio and its affiliated entities, as well as pediatric research at Children's Hospital of San Antonio and Methodist Children's Hospital of South Texas.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, neurological conditions, and liver health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor (5 trials)
• Amyotrophic lateral sclerosis (3 trials)
• Idiopathic hypersomnia (2 trials)
• Lower extremity (2 trials)
• Acute leukemia (2 trials)
• Liver fibrosis (2 trials)
• Healthy (2 trials)
• Cirrhosis, liver (2 trials)
• Anatomic stage ii breast cancer ajcc v8 (1 trial)
• Amyloid plaque (1 trial)

Broadening Your Search: Nearby Options in Texas

While San Antonio offers a robust array of clinical trial opportunities, individuals may also find options in nearby communities within Texas. Cities with active trials include Houston (26 trials), Dallas (15 trials), Austin (8 trials), Fort Worth (4 trials), Galveston (3 trials), Irving (2 trials), Plano (2 trials), and Frisco (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 15 new trials launched this month, 1 includes children and 14 include older adults, ensuring that these populations have ample opportunity to contribute to medical science. Industry sponsors like Eli Lilly and Company, Bayer, and Incyte Corporation are driving significant research efforts in San Antonio, accounting for 14 of the new trials.

As we move further into spring, San Antonio's research community will continue to advance medical innovation, with ongoing enrollment in these significant trials and the exploration of new therapeutic strategies.